|
| Press Releases |
|
 |
|
| Thursday, July 29, 2021 |
|
|
Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 20th consecutive year since its initial inclusion in 2002. more info >> |
|
| Tuesday, July 27, 2021 |
|
|
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021 |
| Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELMTM (aducanumab-avwa) injection 100 mg/mL solution at the AAIC. more info >> |
|
| Friday, July 23, 2021 |
|
|
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma |
| Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma. more info >> |
|
| Wednesday, July 21, 2021 |
|
|
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021 |
| Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
| Monday, July 19, 2021 |
|
|
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand |
| Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand. more info >> |
|
| Thursday, July 1, 2021 |
|
|
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong |
| Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Thursday, June 24, 2021 |
|
|
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401) |
| Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
| Wednesday, June 23, 2021 |
|
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma |
| Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
| Friday, June 18, 2021 |
|
|
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate |
| Eisai Co., Ltd. and Bristol-Myers Squibb Company announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). more info >> |
|
| Tuesday, June 15, 2021 |
|
|
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
TruMerit Launches Global Credential for First-Level, General Nurses
Aug 6, 2025 09:00 HKT/SGT
|
|
|
NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts
Aug 5, 2025 23:22 HKT/SGT
|
|
|
Robot Boom in HK: Shoucheng Holdings at the Forefront
Aug 5, 2025 23:18 HKT/SGT
|
|
|
MHI Selected to Enter Next Stage Procurement Process for Australia's New General-Purpose Frigates
Aug 5, 2025 22:02 JST
|
|
|
Traveler Care Launches Global Medical Dispatch Platform to Help Travel Insurance Companies Cut ER Claims by 80%
Aug 4, 2025 21:00 HKT/SGT
|
|
|
Atlas Lithium's Neves Project Completes Definitive Feasibility Study Estimating 145% IRR and 11-Month Payback
Aug 4, 2025 20:39 HKT/SGT
|
|
|
12 New Companies Join Toyota Woven City as Inventors
Aug 4, 2025 21:09 JST
|
|
|
Honda HRC Wins 46th Suzuka 8 Hours Endurance Road Race
Aug 4, 2025 20:43 JST
|
|
|
'Waste-to-Value, Industry Upgrade, and GBA Co-Creation' Technology Forum Brings Together Top Experts, Driving Green Industry Advancement Through Frontier Technologies 
Aug 4, 2025 11:19 HKT/SGT
|
|
|
MUFG Bank and Fujitsu collaborate on preventive health ecosystem to address societal challenges
Aug 4, 2025 11:00 JST
|
|
|
Michael Owen Becomes the New Face of GK8: Fastest Growing iGaming Brand
Aug 3, 2025 13:00 HKT/SGT
|
|
|
Risetcar's driverless taxis are performing well in the US, with Jakarta operations set to launch soon
Aug 2, 2025 21:30 HKT/SGT
|
|
|
Kuvi.ai Launches Private Beta of Agentic Finance OS with Seed Round Led by Moon Pursuit Capital
Aug 2, 2025 11:30 HKT/SGT
|
|
|
Rust Mobile Revealed With Official Trailer, First Hands-on Demo Set for Gamescom 2025
Aug 2, 2025 00:30 HKT/SGT
|
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Aug 2, 2025 00:02 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
